• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Insights from AUA 2025, including anticipated presentations, key takeaways, and how new research in metastatic prostate ...

Dr Mohammad Mahmoud shares anticipated updates on evolving local treatments, PSMA-based therapies, and impactful genetic studies.

This is the first trial to prospectively demonstrate the impact of bone-protecting agents use on fracture risk for men receiving an androgen receptor pathway inhibitor.

Cleveland Clinic Abu Dhabi, part of the M42 group, has achieved a historic milestone in global healthcare. In collaboration ...

The study advanced beyond a one-size-fits-all model by developing both a global XGBoost classifier and cancer-type-specific ...

The quest for more effective cancer radiotherapy continues apace, with Telix Pharmaceuticals (ASX:TLX) today reporting “encouraging” preliminary results from its phase II study to treat recurrent high ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant prostate cancer has been dosed. The first dose of 67 Cu-SAR-bisPSMA has been ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...